Executive Summary
Generated July 30, 2026
AI Labs
Tempus AI
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Steady
Momentum
insider filing activity unchanged since last check
Headquarters
Chicago, Illinois, USA
Website
Employees
2,600 (2025, approximate)
Founded
2015
Listing
TEM · NASDAQ
Market Cap
$7.72B
Revenue (TTM)
$1.36B
Price
USD42.9 (-12.41%)
Market data as of Jul 29, 2026, 11:25 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
A precision medicine company applying AI to genomic sequencing and clinical data, combining diagnostics and data-licensing businesses to accelerate oncology treatment decisions and drug development. Tempus AI reported Q1 2026 revenue of $348.1 million (up 36.1% year-over-year), with Diagnostics revenue of $261.1 million (driven by 28% oncology volume growth); minimal residual disease test volume reached approximately 6,500 tests in Q1 2026, up roughly 500% year-over-year.
Strategic Connections
- Amazon Web Services: Tempus AI relies predominantly on Amazon Web Services for cloud infrastructure, using AWS for the majority of its data storage and processing needs alongside a smaller Google Cloud commitment.
- Healthcare & Life Sciences: Tempus AI operates within the healthcare and life sciences industry, applying AI to genomic sequencing, diagnostics, and precision oncology.
Strategic Risks
- Healthcare data and diagnostics business faces regulatory and reimbursement complexity
Future Outlook
- Continued growth in oncology diagnostics volume and data-licensing revenue toward sustained profitability
Sources
3 sources, 84% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.